Latest & greatest articles for hydralazine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydralazine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydralazine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydralazine

1. Hydralazine

Hydralazine Top results for hydralazine - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydralazine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial

Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial 28867601 2017 12 11 2018 01 11 1097-6868 217 6 2017 12 American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial. 687.e1-687.e6 S0002-9378(17)30965-1 10.1016/j.ajog.2017.08.018 There is a paucity of good quality evidence regarding the best therapeutic option for acute control (...) of blood pressure during acute hypertensive emergency of pregnancy. We sought to compare the efficacy of intravenously administered hydralazine and oral nifedipine for acute blood pressure control in acute hypertensive emergency of pregnancy. In this double-blind, randomized, controlled trial, pregnant women (≥24 weeks period of gestation) with sustained increase in systolic blood pressure of ≥160 mm Hg or diastolic blood pressure of ≥110 mm Hg were randomized to receive intravenous hydralazine

EvidenceUpdates2018

3. Outcomes of hydralazine induced renal vasculitis

Outcomes of hydralazine induced renal vasculitis DOI: 10.5152/eurjrheum.2017.17075 Outcomes of hydralazine induced renal vasculitis Introduction Hydralazine hydrochloride is an FDA-approved medication for the treatment of essential hypertension. Hydralazine is also recommended by the American Heart Association (AHA) for the treatment of congestive heart failure in African-Americans (1). Among many adverse effects, the auto-immunogenic capability of hydralazine has been shown through its ability (...) to induce lupus and vasculitis (2-4). Hydralazine-induced lupus was first described in 1953. Hydralazine-induced lupus differs from idiopathic lupus both clinically and serologically. Hydralazine-induced lupus rarely involves the kidneys or nervous system, and serologi- cally, while all patients are positive for ANA, they do not have positive double-stranded DNA or hypocom- plementemia. In contrast to hydralazine-induced lupus, hydralazine-induced vasculitis can be severe with frequent involvement

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

4. Hydralazine in infants with persistent hypoxemic respiratory failure.

Hydralazine in infants with persistent hypoxemic respiratory failure. BACKGROUND: Most deaths of infants with chronic lung disease (CLD) are caused by respiratory failure, unremitting pulmonary artery hypertension (PAH) with cor pulmonale, or infection. Although the exact prevalence of PAH in infants with CLD is unknown, infants with CLD and severe PAH have a high mortality rate. Except for oxygen supplementation, no specific interventions have been established as effective in the treatment (...) for PAH in premature infants with CLD. Little has been proven regarding the clinical efficacy of vasodilators and concerns remain regarding adverse effects. OBJECTIVES: To review current evidence for the benefits and harms of hydralazine therapy to infants with persistent hypoxemic respiratory failure. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE via PubMed and EMBASE, and other clinical trials registries through November 2011

Cochrane2013

5. Hydralazine for essential hypertension.

Hydralazine for essential hypertension. BACKGROUND: Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative (...) effectiveness compared to placebo on surrogate and clinical outcomes is justified. OBJECTIVES: To quantify the effect of hydralazine compared to placebo in randomized controlled trials (RCTs) on all cause mortality, cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood pressure in patients with primary hypertension. SEARCH METHODS: We searched the following databases: Cochrane Central Register of Controlled Trials (2011, Issue 3

Cochrane2011

6. Hydralazine for essential hypertension.

Hydralazine for essential hypertension. BACKGROUND: Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative (...) effectiveness compared to placebo on surrogate and clinical outcomes is justified. OBJECTIVES: To quantify the effect of hydralazine compared to placebo in randomized controlled trials (RCTs) on all cause mortality, cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood pressure in patients with primary hypertension. SEARCH STRATEGY: We searched the following databases: Cochrane Central Register of Controlled Trials (to Second Quarter

Cochrane2010

7. Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patie

Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patie Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients Article Text Therapeutics Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients Free Barry M Massie , MD Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2006

8. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. 15533851 2004 11 11 2004 11 22 2013 11 21 1533-4406 351 20 2004 Nov 11 The New England journal of medicine N. Engl. J. Med. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. 2049-57 We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response (...) to this therapy. A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. The study was terminated early owing

NEJM2004

9. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis

Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis Magee L A, Cham C, Waterman E J, Ohlsson A, von Dadelszen P CRD summary This review compared the effects of hydralazine with other antihypertensives for the treatment of severe hypertension in pregnancy. The authors concluded that the findings are not robust enough (...) to guide clinical practice, though they do not support the use of hydralazine. The conclusions follow from the evidence presented, although there were some weaknesses in the conduct of the review. Authors' objectives To evaluate the effects of hydralazine in comparison with other antihypertensives for the treatment of severe hypertension in pregnancy. Searching MEDLINE was searched for articles published in any language from 1966 to September 2002; the search terms were reported. The journal

DARE.2003

10. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. 2057035 1991 08 01 1991 08 01 2013 11 21 0028-4793 325 5 1991 Aug 01 The New England journal of medicine N. Engl. J. Med. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. 303-10 To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects (...) of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. Mortality after two years was significantly lower

NEJM1991